Request for Covid-19 Impact Assessment of this Report

Pharmaceuticals

Hepatitis C Drug Market for (Hospitals, Private Labs, Physician Offices, Public Health Labs and Blood Banks) by Application - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 - 2021

  • ZIO1027759
  • 110 Pages
  • June 2016
  • Pharmaceuticals
Download Sample    Get Discount   
 

The report covers forecast and analysis for the market on a global and regional level. The study provides historic data of hepatitis C drug market 2015 along with a forecast from 2016 to 2021 based on revenue (USD billion). The study includes drivers and restraints for the hepatitis C drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hepatitis C drug market on a global level.

In order to give the users of this report a comprehensive view on the hepatitis C market, we have included a detailed competitive scenario and type portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the hepatitis C drug market has also been included. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.

The study provides a decisive view on the hepatitis C drug market by segmenting the market based on applications. All the application segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Hospitals, private labs, physician offices, public health labs, and blood banks are the key application of the hepatitis C drug market. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa with its further bifurcation into major countries including U.S., Canada, Germany, France, UK, China, Japan, India and Brazil. This segmentation includes demand for hepatitis C drug based on individual applications in all the regions and countries.

Some of the key player in the hepatitis C drug market includes Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.

The report segments the global hepatitis C drug market as

Hepatitis C Drug Market: Application Segment Analysis

  • Hospitals
  • Private labs
  • Physician offices
  • Public health labs
  • Blood banks

Hepatitis C Drug Market: Regional Segment Analysis

  • North America

    • U.S.

  • Europe

    • Germany
    • UK
    • France

  • Asia Pacific

    • China
    • Japan
    • India

  • Latin America

    • Brazil

  • Middle East and Africa

  • Chapter 1. Preface

    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology

      • 1.3.1. Market research process
      • 1.3.2. Market research methodology

  • Chapter 2. Executive Summary

    • 2.1. Global hepatitis C drug market, 2015 - 2021, (USD Billion)
    • 2.2. Hepatitis C drug: market snapshot

  • Chapter 3. Hepatitis C Drug Market: Industry Analysis

    • 3.1. Hepatitis C drug : Market dynamics
    • 3.2. Market Drivers

      • 3.2.1. Increasing incidences of the disease
      • 3.2.2. New efficient therapies and comparatively smaller period of treatment
      • 3.2.3. Rising government funding

    • 3.3. Restraints

      • 3.3.1. Lack of awareness and information about HCV
      • 3.3.2. Treatment cost
      • 3.3.3. Threat related with regulation and development of drug

    • 3.4. Opportunity

      • 3.4.1. Advancing technologies and ongoing research

    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis

      • 3.6.1. Market attractiveness analysis by application segment
      • 3.6.2. Market attractiveness analysis by regional segment

  • Chapter 4. Global hepatitis C drug market: Competitive Landscape

    • 4.1. Company Market Share Analysis

      • 4.1.1. Global hepatitis C drug market: company market share, 2015

    • 4.2. Strategic Development

      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Product and Regional Expansion

    • 4.3. Price Trend Analysis
    • 4.4. Product Portfolio
    • 4.5. Patent Analysis (2011-2016)

      • 4.5.1. Patent Trend
      • 4.5.2. Patent Share by company
      • 4.5.3. By Region

  • Chapter 5. Global hepatitis C market: Application Overview

    • 5.1. Global hepatitis C drug market share, by application, 2015 and 2021
    • 5.2. Global hepatitis C drug market for hospitals, 2015 - 2021(USD Billion)
    • 5.3. Global hepatitis C drug market for private labs , 2015 - 2021 (USD Billion)
    • 5.4. Global hepatitis C drug market for physician offices, 2015 - 2021 (USD Billion)
    • 5.5. Global hepatitis C drug market for public health labs, 2015 - 2021 (USD Billion)
    • 5.6. Global hepatitis C drug market for blood banks, 2015 - 2021 (USD Billion)

  • Chapter 6. Global hepatitis C drug market: Regional Analysis

    • 6.1. Global hepatitis C drug market: Regional overview

      • 6.1.1. Global hepatitis C drug market share, by region, 2015 and 2021

    • 6.2. North America

      • 6.2.1. North America hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.2.2. U.S.
      • 6.2.3. U.S. hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

    • 6.3. Europe

      • 6.3.1. Europe hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.3.2. UK

        • 6.3.2.1. UK hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

      • 6.3.3. France

        • 6.3.3.1. France hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

      • 6.3.4. Germany

        • 6.3.4.1. Germany hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

    • 6.4. Asia Pacific

      • 6.4.1. Asia-Pacific hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.4.2. China

        • 6.4.2.1. China hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

      • 6.4.3. Japan

        • 6.4.3.1. Japan hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

      • 6.4.4. India

        • 6.4.4.1. India hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

    • 6.5. Latin America

      • 6.5.1. Latin America hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
      • 6.5.2. Brazil

        • 6.5.2.1. Brazil hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

    • 6.6. Middle East & Africa

      • 6.6.1. Middle East & Africa hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)

  • Chapter 7. Company Profiles

    • 7.1. Merck & Co

      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product portfolio
      • 7.1.4. Business strategy
      • 7.1.5. Recent developments

    • 7.2. Kenilworth

      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product portfolio
      • 7.2.4. Business strategy
      • 7.2.5. Recent developments

    • 7.3. Roche

      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product portfolio
      • 7.3.4. Business strategy
      • 7.3.5. Recent developments

    • 7.4. Basel Glaxosmith

      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product portfolio
      • 7.4.4. Business strategy
      • 7.4.5. Recent developments

    • 7.5. Gilead Sciences

      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product portfolio
      • 7.5.4. Business strategy
      • 7.5.5. Recent developments

    • 7.6. Abbvie

      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product portfolio
      • 7.6.4. Business strategy
      • 7.6.5. Recent developments

    • 7.7. Bristol- Myers Squibb.d

      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product portfolio
      • 7.7.4. Business strategy
      • 7.7.5. Recent developments

    • 7.8. Johnson & Johnson

      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product portfolio
      • 7.8.4. Business strategy
      • 7.8.5. Recent Developments

  • Chapter 8. Patents

    • 8.1. U.S. (US Patents)
    • 8.2. Europe (EP documents)
    • 8.3. Japan (Abstracts of Japan)
    • 8.4. Global (WIPO (PCT))

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...

  • Publish Date: November 14, 2017
  • $5370
Global Cord Blood Banking Services (Stem Cell) Market, Size, Share, Trends, Forecast, Global Analysis, Research, Report, Segmentation, and Future Demand, 2012 - 2020

Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...

  • Publish Date: July 20, 2017
  • $5370